Tamiya, Eiji
Yamashita, Haruyo
Takabe, Tomosato
Matsumoto, Takahiro
Kajihara, Jun
Yamamoto, Shouichi
Kanoh, Tatsuji
Koide, Hikaru
Minamino, Tohru
Article History
Accepted: 30 December 2021
First Online: 29 January 2022
Declarations
:
: This study was funded by Fuji Yakuhin Co., Ltd., the manufacturer and distributor of topiroxostat.
: The authors have no other conflicts of interest to disclose in connection with the publication of the study results.
: This study was approved by the Ethics Committee of Koto Hospital and was conducted in accordance with the “Ethical Guidelines for Medical Research Involving Human Subjects”. The study procedures adhered to the Declaration of Helsinki and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement, and the study was registered with the University Hospital Medical Information Network (UMIN000039120).
: Written or oral patient consent was not obtained as the medical records of each patient were extracted retrospectively. The opt-out right was provided to patients when displaying the study’s implementation on hospital notices.
: Not applicable.
: Data used in this study are not publicly available. The anonymized dataset was on a file at Koto Hospital.
: Not applicable.
: ET participated in the research design preparation and checked the statistical analysis plan. ET, HY, TT, TM, JK, and SY managed patient clinical records. ET drafted the manuscript, TK and HK reviewed the manuscript, and all authors approved the final manuscript.